NovaBridge Biosciences reported cash from operations of -$14.60M and free cash flow of -$14.60M for the quarter ended Dec 2025, down 33.3% year over year. This cash flow statement covers 16 quarters of results from Sep 2019 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2019 | Dec2019 | Jun2020 | Sep2020 | Dec2020 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||
| Net Income | -35.10M | -49.46M | 1.77M | 157.16M | -61.47M | -33.26M | -67.90M | -15.29M | 25.07M | -20.49M | -10.84M | -3.15M | -1.85M | -6.83M | -72.86M | |
| Depreciation and Depletion | 0.43M | 0.38M | 0.76M | 0.02M | 0.02M | 0.02M | 0.01M | |||||||||
| Share-based Compensation | 0.00M | 23.52M | 15.22M | 0.32M | 0.82M | 1.46M | 3.94M | |||||||||
| Cash from Discontinued Operations | -30.64M | -33.64M | 26.46M | 7.84M | ||||||||||||
| Gains from Sales and Divestitures | 34.36M | -34.38M | ||||||||||||||
| Gains from Investment Securities | -0.05M | -0.31M | -1.32M | |||||||||||||
| Asset Writedowns and Impairment | -1.25M | |||||||||||||||
| Cash from Operations | -30.64M | 153.34M | 8.42M | -10.95M | 1.84M | -14.60M | ||||||||||
| Depreciation, Depletion & Amortization | ||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.43M | 0.38M | 0.76M | 0.02M | 0.02M | 0.02M | 0.01M | |||||||||
| Change in Working Capital | ||||||||||||||||
| Change in Accured Expenses | 22.16M | 0.28M | 28.87M | -0.24M | -3.31M | 8.64M | 10.71M | |||||||||
| Other Working Capital Changes | 0.13M | -0.41M | -0.29M | -0.18M | -0.18M | -0.21M | -0.21M | |||||||||
| Investing Activities | ||||||||||||||||
| Capital Expenditures | -1.08M | -0.67M | -0.49M | -0.00M | -0.04M | |||||||||||
| Change in Acquisitions & Divestments | -6.53M | -22.80M | -335.15M | -57.79M | -81.43M | |||||||||||
| Cash from Investing Activities | 10.97M | -41.43M | 8.22M | -104.97M | ||||||||||||
| Financing Activities | ||||||||||||||||
| Other financing activities | -3.22M | |||||||||||||||
| Change in Capital Stock | ||||||||||||||||
| Shares Issued | 35.97M | 37.53M | 38.45M | |||||||||||||
| Net Equity Issued and Repurchased | 1.28M | |||||||||||||||
| Misc. | ||||||||||||||||
| Cash from Financing Activities | 16.07M | 280.56M | 127.47M | -3.84M | 60.75M | -60.75M | ||||||||||
| Exchange Rate Effect | -8.86M | -3.23M | -17.61M | 40.60M | -13.55M | -3.69M | 1.02M | -0.35M | 1.07M | -0.01M | 0.00M | 0.01M | 0.07M | 0.19M | ||
| Change in Cash | -12.45M | 202.27M | 271.42M | -72.63M | -11.06M | 62.66M | -17.43M | |||||||||
| Free Cash Flow | -29.56M | 0.67M | 153.83M | 8.42M | -10.91M | 1.84M | -14.60M | |||||||||
| Net Cash Flow | -3.60M | 239.14M | 289.03M | 8.42M | -14.79M | -42.38M | -75.34M |
Pull NovaBridge Biosciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NBP&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NBP", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NBP&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();